Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Mar 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well patients can respond to vaccines after receiving CAR-T cell therapy, a treatment for certain blood cancers. Researchers want to find out if patients lose their immunity to diseases that vaccines usually protect against, whether current recommendations for getting vaccinated again are enough to restore that protection, and how quickly any regained immunity might decrease. They are also looking to see if some medical or biological factors can help predict how well a patient responds to vaccines after this type of therapy.

To participate in this study, you need to be at least 18 years old and have a specific type of blood cancer, such as B-cell acute lymphoblastic leukemia or multiple myeloma, and be planning to receive CAR-T cell therapy. Participants will be closely monitored to understand their vaccine response after treatment. If you or a loved one meets these criteria, joining the trial could help contribute valuable information that may benefit future patients undergoing similar therapies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient ≥ 18 years old
• • Suffering from a B-cell malignancy (B-cell acute lymphoblastic leukemia (ALL), B-cell non-hodgkin lymphoma (NHL), Follicular lymphoma (FL), Mantle Cell Lymphoma (MCL), Multiple myeloma (MM))
• • Planned for a CAR-T cell therapy
• • Provided written informed consent
• Exclusion Criteria:
• • Previous or already started CAR-T cell therapy
• • \< 18 years old
• • Lack of consent